TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~-Participants diagnosed as Functional Dyspepsia according to Rome III criteria.~Exclusion criteria:~* Participants with neuropsychiatric disorder.~* Participants diagnosed with irritable bowel syndrome, inflammatory bowel disease and serious constipation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rabeprazole 10 mg (Type: EXPERIMENTAL): None
- Rabeprazole 20 mg (Type: EXPERIMENTAL): None
- Rabeprazole 40 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* anti-HCV and HCV RNA positive,~* interested in starting HCV treatment at the time of diagnosis~* Women of childbearing potential engaged in sexual activity that could lead to pregnancy~* must consent to use contraception and agree to pregnancy testing during treatment~* If currently not enrolled in insurance, agree to assistance to enroll in insurance~Exclusion Criteria:~* HBsAg positive from pre-screening visit and no medically controlled hepatitis B virus (HBV) condition~* History of hepatic decompensation (ascites, hepatic encephalopathy, or variceal hemorrhage).~* Current use of medications that is not compatible with SOF/VEL use, according to current prescribing guidelines, including amiodarone or a proton pump inhibitor exceeding 20 mg of omeprazole equivalent.~* Prior treatment with an NS5a based HCV treatment regimen with subsequent viral rebound. Participants who have clear HCV reinfection as defined by an HCV GT that is different from the original genotype may enroll. If genotype results are not available from the initial and subsequent HCV infection, the individual will not be enrolled unless participant can provide SVR-12 record confirming HCV cure.~* Pregnancy or breastfeeding.~* Life expectancy of \< 12 months as assessed by study clinical health provider.~* Late exclusion criteria: Participants with the following lab values at week 0 will be evaluated on a case by case basis for continuation of SOF/VEL at the week 2 visit~* Albumin \< 3.0~* Hemoglobin \< 8.0 (women) and \< 9.0 g/dl ( men)~* Platelet count \< 50,000~* creatinine (Cr) clearance (estimated by Cockcroft-Gault) \< 30 ml/min~* aspartate aminotransferase (AST) or Alanine Aminotransferase (ALT) \> 10 x ULN~* Total bilirubin \> 1.5x ULN (for participants on atazanavir, \> 3 x ULN), international normalized ratio (INR) \> 1. 5 x ULN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- at Point-of-Diagnosis HCV treatment (Type: EXPERIMENTAL): At the point of HCV infection diagnosis, (HCV RNA positive and anti-HCV positive) individuals who meet eligibility criteria and elect to start HCV treatment at the same visit and monitored at two-week intervals at the community-site.
- Passive observation (Type: ACTIVE_COMPARATOR): Participants who test positive for HCV chronic infection (HCV RNA positive, and anti-HCV positive) but elect to not enroll in the intervention arm. Electronic medical record data will be reviewed for up to 2 years for HCV related care information (e.g., HCV treatment start date, end date, SVR-12).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with T1DM for at least 2 years and who have used an insulin delivery system with any rapid-acting insulin analog for the preceding 6 months~* Have a body mass index of 18.5 to 37 kilogram per meter squared~* Have a hemoglobin A1c level ≥6.0% and ≤9.0%~Exclusion Criteria:~* Have known allergies or history of hypersensitivity to insulin lispro~* Have had an episode of severe hypoglycemia within the past 6 months~* Have had more than 1 episode of diabetic ketoacidosis in the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AID System Containing Insulin Lispro (Type: EXPERIMENTAL): The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Metastatic disease progressing despite castrate levels of testosterone~* Prostate cancer progression documented by PSA~* Surgically or medically castrated, with testosterone levels of \< 50 ng/dL~* Previous anti-androgen therapy and progression after withdrawal~* ECOG performance status of 0 to 1~* Adequate organ function~* Prior radiation therapy allowed to \< 25% of the bone marrow~* Prior hormonal therapy is allowed~* Patient compliance and geographic proximity that allow adequate follow-up.~* Patients with reproductive potential must use contraceptive methods~* Signed informed consent from patient~Exclusion Criteria:~* Active infection~* Any chronic medical condition requiring a high doses of corticosteroid~* Pathological finding consistent with small cell carcinoma of the prostate~* Brain metastasis~* Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC~* Radiation therapy for treatment of the primary tumor within 6 weeks~* Radionuclide therapy for treatment of metastatic CRPC~* Prior systemic treatment with an azole drug~* Prior flutamide treatment within 4 weeks~* Prior bicalutamide or nilutamide within 6 weeks~* Congenital long QT syndrome, congestive heart failure, or bradyarrhythmia~* Administration of an investigational therapeutic within 2 weeks~* Second primary malignancy~* Presence of clinically detectable third-space fluid collections~* History of severe hypersensitivity reaction to polysorbate 80~* Peripheral neuropathy at study entry

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIND-014 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men \& women ≥20 years of age~* Histologically confirmed unresectable advanced or recurrent esophageal cancer~* Refractory to or intolerant of standard therapy~* ECOG Performance Status score 0 or 1~* A life expectancy of at least 3 months~Exclusion Criteria:~* Current or past history of severe hypersensitivity to any other antibody products~* Patients with multiple primary cancers~* Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment~* Patients with active, known or suspected autoimmune disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab Arm (Type: EXPERIMENTAL): Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
- Active Comparator Arm （Docetaxel/Paclitaxel） (Type: ACTIVE_COMPARATOR): Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~OR~Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female between 18 and 45 years of age.~2. Female subjects must agree to use a medically acceptable method of contraception at all times during the study and must have a negative serum pregnancy test at baseline and during the study period.~3. Females of child-bearing potential must be non-pregnant and not lactating and using adequate birth control such as oral contraceptives.~4. Negative laboratory tests for HIV, HBsAg or HCV.~5. Naive to any previous recombinant protein therapy.~6. Provide written informed consent.~7. Have the ability to understand the requirements of the study and to comply with the study protocol and dosing regimen.~Exclusion Criteria:~1. Have clinical evidence of any active significant disease that could potentially compromise the ability of the investigator to evaluate or interpret the effects of the study treatment on safety assessment and thus increase the risk to the subject to unacceptable levels.~2. Are pregnant or nursing.~3. Presence of any acute or chronic diseases.~4. Have a history of any allergies.~5. Have been exposed to long-term steroid treatment.~6. Had a minor operation in the last 6 months.~7. Have ever been exposed to any previous recombinant protein therapy.~8. Have received immuno-suppressive treatment.~9. Have a positive HIV, HBsAG and HCV laboratory result.~10. Use any medication other than vitamins or oral contraceptives (for female).~11. Have participated in another clinical trial during the previous 3 months~12. Have history of alcohol or drug abuse.~13. Are considered by the Investigator to be unsuitable candidate for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking~* ASA Physical Status I-II~* Non-laboring women~* Single gestations ≥ 36 weeks~* Obese women (Body Mass Index 35 - 55 kg/m2)~* Non-emergent CD under spinal anesthesia~Exclusion Criteria:~* Height \< 5'0~* Antiemetic drug use in the 24 hours prior to CD~* Allergy to phenylephrine, or any other standardized medication~* Hypertensive disease of pregnancy (i.e. mild \& severe preeclampsia)~* Chronic hypertension receiving antihypertensive treatment~* Severe Cardiac disease in pregnancy with marked functional limitations~* Patients on Monoamine Oxidase Inhibitors or Tricyclic Antidepressants~* Subject enrollment in another study involving a study medication within 30 days of CD~* Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phenylephrine bolus (Type: EXPERIMENTAL): None
- Phenylephrine infusion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult women with locoregionally recurrent or metastatic disease not amenable to curative therapy.~* Confirmed diagnosis of ER positive breast cancer~* No prior systemic anti-cancer therapy for advanced ER+ disease.~* Postmenopausal women~* Measurable disease as per Response Evaluation Criterion in Solid Tumors \[RECIST\] or bone-only disease~* Eastern Cooperative Oncology Group \[ECOG\] 0-2~* Adequate organ and marrow function~* Patient must agree to provide tumor tissue~Exclusion Criteria:~* Confirmed diagnosis of HER2 positive disease~* Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term~* Known uncontrolled or symptomatic CNS metastases~* Prior (neo)adjuvant treatment with letrozole or anastrozole with DFI ≤ 12-months from completion of treatment.~* Prior treatment with any CDK 4/6 inhibitor.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PD-0332991 + Letrozole (Type: EXPERIMENTAL): PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
- Placebo + Letrozole (Type: ACTIVE_COMPARATOR): Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female patients between the ages of 18 and 75 years~* Patients must have moderate to severe erosive esophagitis~Exclusion Criteria:~* Significant gastrointestinal bleeding~* Severe heart, lung, liver or kidney disease~* Esophagitis not related to acid reflux

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Be in good general health~* Be able to participate for 4-15 months~Exclusion Criteria:~* Pregnant or planning pregnancy~* History of malaria or exposure to malaria in past 12 months~* Received an investigational malaria vaccine~* Past history of allergic reaction to previous immunization~* Positive blood tests for HIV and specific types of hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participant had CKD requiring dialysis or CKD not on dialysis with an estimated glomerular filtration rate (GFR) \<60 mL/min/1.73 m\^2 based on central laboratory results.~* The participant had a serum phosphorus level greater than the age appropriate upper limit of normal based on central laboratory results.~Exclusion Criteria:~* The participant had active dysphagia, swallowing disorders or a predisposition to or current bowel obstruction, ileus or severe gastrointestinal motility disorder(s) including severe constipation, or major gastrointestinal tract surgery.~* The participant had a non-renal case of hyperphosphatemia.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- FDP-Placebo for Sevelamer Carbonate, DTP-Sevelamer Carbonate (Type: PLACEBO_COMPARATOR): Participants received placebo for 2 weeks during the fixed dose period (FDP). Participants received sevelamer carbonate for 26 weeks in dose titration period (DTP).
- FDP-Sevelamer Carbonate, DTP-Sevelamer Carbonate (Type: EXPERIMENTAL): Participants received sevelamer carbonate for 2 weeks during the FDP of the study. Participants received sevelamer carbonate for an additional 26 weeks in DTP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 21-79~* Body mass index (BMI) of 30-40 kg/m2~* Non-insulin-dependent type-2 diabetics (as confirmed by hemoglobin A1c (HbA1c) of \> 6.4% and/or fasting plasma glucose of \>125 mg/dL or current anti-diabetic medication)~* AA-induced platelet aggregation response of \>60% within 3 hours prior to initial dose of study drug administration~Exclusion Criteria:~* Contraindications to aspirin~* Previous history of vascular disease~* Patient requires insulin~* Use of non-steroidal anti-inflammatory drugs, anti-secretory agents, antacids, and salicylate-containing nutritional supplements within 2 weeks of randomization

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- PL2200 Aspirin Capsules (Type: EXPERIMENTAL): Investigational drug arm; crossover design
- Immediate-Release Aspirin Tablets (Type: ACTIVE_COMPARATOR): Active comparator; crossover design
- Enteric-coated aspirin caplets (Type: ACTIVE_COMPARATOR): Active comparator; crossover design

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Breathing and Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic obstructive pulmonary disease (COPD), GOLD grade 2-3~* residents at low altitude (\<800 m)~Exclusion Criteria:~* unstable condition, COPD exacerbation~* mild (GOLD 1) or very severe COPD (GOLD 4)~* requirement for oxygen therapy at low altitude residence~* hypoventilation~* pulmonary hypertension~* more than mild or unstable cardiovascular disease~* use of drugs that affect respiratory center drive~* internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day), inability to perform 6 min walk test.~* previous intolerance to moderate altitude (\<2600m).~* exposure to altitudes \>1500m for \>2 days within the last 4 weeks before the study.~* pregnant or nursing patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Oxygen (Type: ACTIVE_COMPARATOR): oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
- Sham oxygen (Type: PLACEBO_COMPARATOR): Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PAH NYHA Class II~* Significant elevation of mean pulmonary arterial pressure~* Significant elevation of pulmonary vascular resistance at rest~* Limited 6-minute walk distance~Exclusion Criteria:~* PAH secondary to portal hypertension, complex congenital heart disease or reverse shunt~* Restrictive or obstructive lung disease~* Significant vasoreactivity~* Treatments for PAH (within 4 weeks of randomization)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 62.5 mg table twice a day for 4 weeks followed by 125 mg tablet twice a day for 6 months followed by an open label period until end of study.
- 2 (Type: PLACEBO_COMPARATOR): placebo for 6 months followed by an open label period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete